Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0345904 (
liver cancer
)
15,188
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Our previous study shows that Calpain 6 (CAPN6) expression is regulated by PI3K-Akt in
liver cancer
through
POU2F1
and CAPN6 which promote cell proliferation and inhibit apoptosis of
liver cancer
cells. microRNAs (miRNAs) plays important roles in regulation of gene expression. However, whether miRNAs regulates CAPN6 expression and its cellular function is still unknown. This study aims to investigate how miRNAs regulate
liver cancer
apoptosis through
POU2F1
-CAPN6. It was verified that
POU2F1
could promote cell proliferation and inhibit apoptosis through CAPN6. Using methods of bioinformatics, miR-449a was predicted as a potential regulator of both CAPN6 and
POU2F1
. It was verified that CAPN6 and
POU2F1
were the target genes of miR-449a by luciferase assay. CAPN6 and POU2F1 protein and mRNA levels decreased in
liver cancer
cells with miR-449a overexpression using western blot and real time RT-PCR assays. miR-449a expression was lower in
liver cancer
tissues compared with their normal ones, so did the cells. Overexpression of miR-449a inhibited cell proliferation, induced G1 phase arrest and cell apoptosis in
liver cancer
. Further research demonstrated that miR-449a inhibited cancer cell proliferation and induced apoptosis via suppressing both
POU2F1
and CAPN6. The study indicated that miR-449a functions as a tumor inhibitor in
liver cancer
by decreasing
POU2F1
and CAPN6 expression in
liver cancer
.
...
PMID:miR-449a promotes liver cancer cell apoptosis by downregulation of Calpain 6 and POU2F1. 2637 40